Curriculum Vitae

Perry Mark ELLIOTT, M.B.,B.S. (London) 1987; M.R.C.P. (UK) 1990; M.D. (London) 2001; F.R.C.P. 2005

Application for the position of Vice President

Personal Information:

Place and Date of Birth: London, United Kingdom. 7th December 1963

Nationality: British

Current Position and Professional Address

Director UCL Institute of Cardiovascular Science; University College London, Rayne Institute, 5 University St., London WC1E 6JF; https://lnkd.in/enYe3VF; https://profiles.ucl.ac.uk/2319-perry-elliott

Education and Postgraduate Training

Education: 1987 St. Thomas's Hospital Medical School (London) MB. BS. Medicine & Surgery; **Post graduate:** 1990 Royal College Physicians (London) MRCP (Medicine); St. George's Hospital Medical School, London MD (2001) & Specialty Certification (2001). **Substantive positions:** Senior Lecturer in Cardiology, St. George's Hospital Medical School, *1999-2003;* Senior Lecturer in Cardiology, University College London (UCL), *2003-2005;* Reader in Inherited Cardiac Disease, UCL, *2005-2012;* Professor of Cardiology, UCL, *2012-present;* Director UCL Institute of Cardiovascular Science, *2022-present.*

European Society of Cardiology Activities

2004-12 European Society of Cardiology: Myocardial Pericardial Diseases (Secretary 2006; Chairman 2010)
2009 European Association of Echocardiography Scientific Programme Committee (member)
2011 ESC Cardiac Pacing and Cardiac Resynchronization Therapy Task Force (member)
2011 ESC Observational Research Programme: Registry on Cardiomyopathies (Chairman)
2012-14 European Society of Cardiology Guideline Taskforce for Hypertrophic Cardiomyopathy (Chairman)
2013 Scientific committee for Survey of the European Cardiovascular Research Landscape (EU & ESC):
2018-20 ESC Congress Programme Committee
2018-24 Chairman European Society of Cardiology Heart Academy
2019-21 ESC Council for Cardiovascular Genomics (Chairman)
2020- Executive Editor; The European Heart Journal
2021-23 European Society of Cardiology Guideline Taskforce for Cardiomyopathy (member)
2022-24 Councillor & Board Member
2024- European Society of Cardiology Think Tank on future careers
2023- ESC Cardiotalks (Host)

Participation in Other International Scientific Committees

2018-20 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (member); **2019** Committee for the Greek National Network of Precision Medicine in Cardiology and the Prevention of Sudden Death in the Young; **2019** Chair International Cardiomyopathy Network

Editorial Boards

Deputy Editor, *Heart* 2009; Consulting Editor, Cardiogenetics 2011 (Online journal; PAGEPress Publications, Pavia, Italy); Associate Editor, Clinical Cardiology, 2011; Section Editor (Genomics) Journal of American College of Cardiology 2014; Editor Cardiovascular Genetics and Genomics, 2014; Section Editor for Education in Heart, The

Heart Journal; Deputy Editor International Journal of Cardiology 2016-2019; Executive Editor; The European Heart Journal 2020-present

Leadership and Management Experience

Perry Elliott has a thorough understanding of the international cardiovascular ecosystem and is a passionate advocate for translational medical research and education. He seeks to nurture and grow a vibrant and successful community of basic and clinical scientists dedicated to a better understanding of the fundamental mechanisms of cardiovascular diseases and their diagnosis, prevention and treatment throughout the life course. He achieves this through consultation and consensus, and by ensuring academic leadership grounded in intellectual excellence.

ACADEMIC LEADERSHIP: He is Director of the **UCL Institute of Cardiovascular Science (2022-)** (https://www.ucl.ac.uk/population-health-sciences/cardiovascular) which brings together basic and clinical scientists and expert clinicians from partner hospitals to provide Innovative research for the prevention and treatment of diseases of the heart and circulation, World-class teaching and training in the Cardiovascular Sciences, and forward-thinking policy development for effective Cardiovascular disease management. This work is interdisciplinary, integrating with Engineering, Nanotechnology, Chemistry, Behavioural Science, Ophthalmology and genetics. He oversees two 4-year interdisciplinary PhD programmes (BHF and MRC), a 180-credit MSc programme, and an integrated BSc in CV Science (one of only 4 in the UK). As director of the **UCL BHF Centre of Research Excellence (2024-)** (https://www.ucl.ac.uk/population-health-sciences/cardiovascular/research/bhf-centre-research-excellence) he has developed (1) springboard fellowships to support promising early career researchers (ECR); interdisciplinary PhDs based on disciplines outside conventional CV research (e.g. social science, economics); and (3) pump-priming grants. Over the past two years, he has created two new research centres (CV prevention and Neurocardiology) to encourage a focus on population health and emergent science.

UK CLINICAL LEADERSHIP ROLES: 2002 Guideline Development Group of the Royal College of physicians/NICE; **2004** Medical Research Council College of Experts; **2005** North Central London Cardiac Network (Heart Failure Group-Chairman); **2006** British Heart Foundation Project Grants Committee (I); **2006** Department of Health: National Coroner/Pathologist Group; **2007** UK Cardiac Pathology Network (Chairman and co-founder); **2007** Expert Consensus Workshop: Driving Safety and Vascular Disease (DVLA); **2008** Fabry Outcome Survey Executive committee/International board; **2008** PHG Foundation genetic services advisory group; **2008** RCP: Chairman Cardiology section "Map of Medicine"; **2008** Clinical lead, Sudden Cardiac Disease Database (CCAD);; **2009** NHS Informal Advisory Group on Inherited Cardiac Conditions; **2010** NCEPOD Surgery in children study Advisory Group; **2011** Cardiac Devices National Action Group (CDNAG); **2013** Advisor to the Department of Health and NHS England; commissioning framework for specialist commissioning of inherited cardiovascular disease services; **2016** British Heart Foundation: Fellowships Committee; **2016** Deputy theme lead (genomics), Biomedical Research Centre, Barts Health Trust; **2017** UCLH Biomedical Research Centre Cardiovascular (and Intensive Care) Theme Board; **2018** UCL Institute for Precision Medicine Steering Committee; **2023** NHS and Coronial Sudden Unexpected Death Pilot Project (Member); **2024** NICE Technology Appraisal Expert Witness.

CONTRIBUTIONS TO WIDER SOCIETY: Cardiomyopathy UK (https://www.cardiomyopathy.org): Perry Elliott bridges scientific, clinical and lay communities through the Presidency of Cardiomyopathy UK, Europe's foremost heart muscle disease charity, where he coordinates PPI activities, online learning and a UK advisory group. In 2019, he formed a charity, **The International Cardiomyopathy Network** (ICoN) (https://www.cardiomyopathy-icon.org) with the mission of improving multi-stakeholder involvement in research, education and advocacy.

Fellowships and Honours

MEMBERSHIP OF SOCIETIES: **1999** British Cardiac Society; **1999** European Society of Cardiology; **1987** British Medical Association; **1999** British Society of Echocardiography; **1999** British Society of Heart Failure; **2003** Royal Society of Medicine; **2009** Founder member UK Association of Inherited Cardiac Conditions

HONOURS: **2001** Fellow American College of Cardiology; **2005** Fellow Royal College of Physicians; **2005** Fellow European Society of Cardiology; **2005** Finalist Cardiac Team of the Year (Hospital Doctor); **2010** National clinical excellence award (Bronze); **2014** Visiting Professor Cleveland Clinic, OH, USA; **2019** NIHR Senior Investigator; **2024 & 2025** Clarivate Highly Cited Researcher in the field of Clinical Medicine; **2025** National Clinical Impact Award (Level 3); **2025** visiting Professor Charles University Prague.

Honorary Memberships

2007 Honorary member Hungarian Society of Cardiology; **2023** Hellenic Heart Failure Research Society; **2025** Honorary Member Czech Cardiac Society

Top 10 Most Relevant Publications

1. Lopes LR, Garcia-Hernández S, Lorenzini M, Futema M, et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. Eur Heart J. 2021;42(32):3063-3073. 10.1093/eurheartj/ehab424.
2. Akhtar MM, Lorenzini M, Pavlou M, et al; European Genetic Cardiomyopathies Initiative Investigators. Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. JAMA Cardiol. 2021 Aug 1;6(8):891-901. DOI: 10.1001/jamacardio.2021.1106.
3. Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the *TTN* Gene. Circ Heart Fail. 2020 Oct;13(10):e006832. doi:10.1161/CIRCHEARTFAILURE.119.006832.
4. Cannie DE, Bakalakos A, Syrris P, et al. Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy. JACC Heart Fail. 2025 Aug 22;13(10):102588. doi: 10.1016/j.jchf.2025.102588.
5. O'Mahony C, Jichi F, Pavlou M, et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. doi: 10.1093/eurheartj/eht439.
6. O'Mahony C, Jichi F, Ommen SR, Christiaans I, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015-1023. doi: 10.1161/CIRCULATIONAHA.117.030437.
7. Protonotarios A, Bariani R, Cappelletto C, al al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J. 2022 Aug 21;43(32):3053-3067. doi: 10.1093/eurheartj/ehac235.
8. Coats CJ, Heywood WE, Virasami A, et al. Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. Circ Genom Precis Med. 2018 Dec;11(12):e001974. doi: 10.1161/CIRCGEN.117.001974
9. Elliott P, Abozguia K (joint first author), McKenna W, et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122(16):1562-9. doi: 10.1161/CIRCULATIONAHA.109.934059.
10. Coats CJ, Pavlou M, Watkinson OT, et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA Cardiol. 2019;4(3):230-235. doi: 10.1001/jamacardio.2018.4847.

Major Research Interests

Perry Elliott is a World authority in heart muscle disease and his work has led to direct benefits for patients, including accurate risk prediction, effective family screening, and prevention of sudden death. His most important contributions are:

1. Gene Discovery and Genotype-Phenotype Analyses: By combining high-throughput gene sequencing technologies with large-scale phenotyping, bioinformatics and functional analyses, Elliott has identified new cardiomyopathy endotypes and discovered novel disease-causing genes (e.g. ALPK3 in hypertrophic cardiomyopathy (HCM). Using cardiomyopathies as models for translation, his work has shown that genetic heterogeneity causes predictable effects on cardiac phenotypes and that genetic testing can be used to guide therapy and counselling strategies.

2. Development and Validation of Clinical Risk Tools: Elliott developed a prediction tool based on a unique European research collaboration–the HCM Investigators–that provides individualised risk estimates for sudden death (SD) for patients with HCM (adopted by the European Society of Cardiology in 2014 and 2023).
In collaborations spanning North America, the Middle East, Japan and Singapore, he demonstrated that the HCM risk tool is predictive in different healthcare settings and ethnicities. He has developed models that have transformed clinical risk stratification in other diseases, including dilated cardiomyopathy (1 in 3 people with heart failure), arrhythmogenic right ventricular cardiomyopathy (a common cause of SD in young people) and rare disorders (mitochondrial disease and glycogen storage diseases).

3. Biomarker Discovery: Elliott has pioneered analysis of the myocardial proteome in cardiomyopathies, providing evidence for dysregulation of metabolic and structural proteins, and proteins associated with muscle contraction, calcium regulation and oxidative stress. His work on the myocardial proteome led to the development of a multiplex biomarker panel for hypertrophic cardiomyopathy using quantitative proteomics and machine learning, providing a paradigm for future high-throughput approaches to the diagnosis of heart muscle disorders. His current work explores the role of autoimmunity in the genesis and outcome of genetic heart muscle diseases.

4. Clinical Trials: By reason of his clinical and trials expertise and insights into the translational pathway and regulatory processes, he plays a leading role in trial design and conduct. He explored the potential therapeutic benefit of altering energy metabolism in patients with HCM using perhexiline and trimetazidine in two investigator-led trials. Recent examples of his contributions to pivotal multicentre studies include tafamidis in cardiac amyloidosis and cardiac myosin inhibitors in hypertrophic cardiomyopathy.